SGLT2 inhibitor lowers risk of kidney failure in type 2 diabetes
Results showed that canagliflozin improved outcomes in type 2 diabetes patients with kidney disease, preventing kidney failure, heart failure and cardiovascular events
Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) have a lower risk of kidney failure and cardiovascular events if they are treated with canagliflozin, research has confirmed.
To investigate, researchers in Sydney, Australia, randomly assigned 4,401 patients with T2DM and CKD to either 100mg of canagliflozin — a sodium-glucose co-transporter 2 (SGLT2) inhibitor — or placebo.
All participants were already being treated with renin-angiotensin system blockade and were followed up for a median of 2.6 years.
Results showed that people taking canagliflozin were 30% less likely than those taking placebo to experience the primary outcome, a composite of end-stage kidney disease; a doubling of the serum creatinine level, which can highlight worsening kidney function; or death from kidney or cardiovascular causes.
Event rates were 43.2 per 1,000 patient years in the canaglifozin group and 61.2 per 1,000 patient-years in the placebo group (hazard ratio [HR] 0.70; 95% confidence interval [CI] 0.59–0.82; P=0.00001).
When kidney-specific outcomes were evaluated, the risk was lowered by 34% (HR 0.66; 95% CI 0.53–0.81; P<0.001).
Vlado Perkovic, lead author and professor of medicine at the George Institute for Global Health in Sydney, Australia, said: “[The] trial provides convincing evidence that canagliflozin improves outcomes in diabetes with kidney disease, preventing kidney failure, heart failure and cardiovascular events.”
Citation: The Pharmaceutical Journal DOI: 10.1211/CP.2019.20206795
Recommended from Pharmaceutical Press